Point72 Asset Management Increases Stake in Design Therapeutics to 5.1%

On June 9, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed a Schedule 13G regarding their holdings in Design Therapeutics, Inc. (DSGN). The filing reports that as of June 8, 2026, the reporting persons collectively beneficially own 3,197,764 shares of common stock, representing 5.1% of the class. This reflects an increase from their previously reported position of 2,722,754 shares (4.4% ownership). The shares are held directly by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. Point72 Capital Advisors, Inc. serves as the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. Sub-advisory roles are held by Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited, and Point72 Asia (Singapore) Pte. Ltd. The filing was made under Rule 13d-1(c), indicating a passive investment intent without the purpose of influencing or changing the control of the issuer.